Quick Answer
Korro Bio, Inc. reported Total Revenue of $6.39 million for fiscal year 2025.
Korro Bio, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $6.39M +181.5% |
$2.27M | $0.00 | $0.00 -100.0% |
$14.07M -62.0% |
$36.98M +27.8% |
| Revenue (ASC 606) | — | — | — | $0.00 -100.0% |
$14.07M -62.0% |
$36.98M +27.8% |
| Net Income | -$117.26M -40.3% |
-$83.58M -3.0% |
-$81.17M -39.9% |
-$58.03M +31.5% |
-$84.69M -219.4% |
-$26.51M -41.4% |
| Diluted EPS | -$12.48 -33.2% |
-$9.37 +82.3% |
-$53.08 +76.7% |
-$227.42 | — | — |
| Total Assets | $113.51M -49.8% |
$226.24M +2.1% |
$221.66M +200.6% |
$73.74M -60.2% |
$185.36M -30.0% |
$264.72M +18.6% |
| Cash and Equivalents | $21.82M -60.8% |
$55.64M +52.0% |
$36.60M +0.7% |
$36.33M -54.4% |
$79.64M -63.9% |
$220.34M +10.1% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $51.44M -67.9% |
$160.41M -5.6% |
$169.91M +271.6% |
-$99.03M -134.6% |
-$42.21M -121.9% |
$192.49M +15.0% |
| R&D Expense | $65.58M +3.0% |
$63.64M +11.2% |
$57.25M +35.7% |
$42.20M -30.7% |
$60.92M +62.8% |
$37.41M +99.2% |
| Operating Income | -$121.86M -32.6% |
-$91.91M -8.7% |
-$84.53M -43.3% |
-$59.00M +29.8% |
-$84.03M -205.0% |
-$27.55M -33.3% |
| Shares Outstanding | 9.42M +0.4% |
9.38M +17.0% |
8.02M +2886.0% |
268,468 -99.2% |
34.61M +1.9% |
33.96M +10.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $1.09M | — | -25.3% |
| Revenue (ASC 606) | September 30, 2022 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$18.06M | +14.0% | +29.9% |
| Diluted EPS | September 30, 2025 | -$1.92 | +15.0% | +29.9% |
| Total Assets | September 30, 2025 | $161.55M | -33.7% | -10.5% |
| Cash and Equivalents | September 30, 2025 | $24.16M | -61.8% | -28.1% |
| Long-Term Debt | December 31, 2019 | $180.0K | -48.4% | -18.9% |
| Stockholders Equity | September 30, 2025 | $99.03M | -44.9% | -14.0% |
| R&D Expense | September 30, 2025 | $13.82M | -13.4% | -34.3% |
| Operating Income | September 30, 2025 | -$19.24M | +17.4% | +29.3% |
| Shares Outstanding | September 30, 2025 | 9.40M | +0.9% | +0.1% |
- Korro Bio, Inc. reported Total Revenue of $6.39 million for fiscal year 2025.
- Korro Bio, Inc. showed an increase of +181.5% in Total Revenue compared to the prior fiscal year.
- Korro Bio, Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2022.
- Korro Bio, Inc. showed a decrease of -100.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Korro Bio, Inc. reported Net Income of -$117.26 million for fiscal year 2025.
- Korro Bio, Inc. showed a decrease of -40.3% in Net Income compared to the prior fiscal year.
- Korro Bio, Inc. reported Diluted EPS of $12.48 per share (loss) for fiscal year 2025.
- Korro Bio, Inc. showed a decrease of -33.2% in Diluted EPS compared to the prior fiscal year.
- Korro Bio, Inc. reported Total Assets of $113.51 million for fiscal year 2025.
- Korro Bio, Inc. showed a decrease of -49.8% in Total Assets compared to the prior fiscal year.
- Korro Bio, Inc. reported Cash and Equivalents of $21.82 million for fiscal year 2025.
- Korro Bio, Inc. showed a decrease of -60.8% in Cash and Equivalents compared to the prior fiscal year.
- Korro Bio, Inc. reported Long-Term Debt of $180.0 thousand for fiscal year 2019.
- Korro Bio, Inc. showed a decrease of -48.4% in Long-Term Debt compared to the prior fiscal year.
- Korro Bio, Inc. reported Stockholders Equity of $51.44 million for fiscal year 2025.
- Korro Bio, Inc. showed a decrease of -67.9% in Stockholders Equity compared to the prior fiscal year.
- Korro Bio, Inc. reported R&D Expense of $65.58 million for fiscal year 2025.
- Korro Bio, Inc. showed an increase of +3.0% in R&D Expense compared to the prior fiscal year.
- Korro Bio, Inc. reported Operating Income of -$121.86 million for fiscal year 2025.
- Korro Bio, Inc. showed a decrease of -32.6% in Operating Income compared to the prior fiscal year.
- Korro Bio, Inc. reported Shares Outstanding of 9.42 million shares for fiscal year 2025.
- Korro Bio, Inc. showed an increase of +0.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: